People with HIV (PWH) on combination antiretroviral therapy (cART) are living longer lives due to modern cART advances and increased routine medical care. The full landscape of aging with HIV is unclear; given that HIV emerged relatively recently in human history and initially had a high mortality rate, there has not been a substantially aged population to evaluate. In this study, we set out to perform high-throughput plasma analyte profiling by multiplex analysis, focusing on various T helper (Th)-related cytokines, chemokines, and proinflammatory and anti-inflammatory cytokines. The primary goals being to provide reference ranges of these analytes for aging PWH cohorts, as well as testing the utility of high-throughput multiplex plasma assays. The cohort used in this study comprised age-matched healthy donors (32.6–73.5 years of age), PWH on cART (26.7–60.2 years of age), and viremic PWH (27.5–59.4 years of age). The patients in each group were then stratified across the age span to examine age-related impacts of these plasma biomarkers. Our results largely indicate feasibility of plasma analyte monitoring by multiplex and demonstrate a high degree of person-to-person variability regardless of age and HIV status. Nonetheless, we find multiple associations with age, duration of known infection, and viral load, all of which appear to be driven by either prolonged HIV disease progression or long-term use of cART.
Get full access to this article
View all access options for this article.
References
1.
MorenoS, PernoCF, MallonPW, et al.Two-drug vs. three-drug combinations for HIV-1: Do we have enough data to make the switch? HIV Med, 2019; 20Suppl 4:2–12; doi: 10.1111/hiv.12716
2.
LongevityTLH. Ageing with HIV. Lancet, 2022; 3(3):e119; doi: 10.1016/S2666-7568(22)00041-1
3.
HarmanD. The aging process: Major risk factor for disease and death. Proc Natl Acad Sci U S A, 1991; 88(12):5360–5363; doi: 10.1073/pnas.88.12.5360
4.
LehallierB, GateD, SchaumN, et al.Undulating changes in human plasma proteome profiles across the lifespan. Nat Med, 2019; 25(12):1843–1850; doi: 10.1038/s41591-019-0673-2
5.
FontelaC, AguinagaA, Moreno-IribasC, et al.Trends and causes of mortality in a population-based cohort of HIV-infected adults in Spain: Comparison with the general population. Sci Rep, 2020; 10(1):8922; doi: 10.1038/s41598-020-65841-0
6.
SmitM, BrinkmanK, GeerlingsS, et al.Future challenges for clinical care of an ageing population infected with HIV: A modelling study. Lancet Infect Dis, 2015; 15(7):810–818; doi: 10.1016/S1473-3099(15)00056-0
7.
RodesB, CadinanosJ, Esteban-CantosA, et al.Ageing with HIV: Challenges and biomarkers. EBioMedicine, 2022; 77:103896; doi: 10.1016/j.ebiom.2022.103896
8.
LemmaM, PetkovS, BekeleY, et al.Profiling of inflammatory proteins in plasma of HIV-1-infected children receiving antiretroviral therapy. Proteomes, 2020; 8(3):24; doi: 10.3390/proteomes8030024
9.
WingEJ. HIV and aging. Int J Infect Dis, 2016; 53:61–68; doi: 10.1016/j.ijid.2016.10.004
10.
FranconiI, GuaraldiG. Pre-exposure prophylaxis for HIV infection in the older patient: What can be recommended?. Drugs Aging, 2018; 35(6):485–491; doi: 10.1007/s40266-018-0553-3
11.
ErlandsonKM, KarrisMY. HIV and aging: Reconsidering the approach to management of comorbidities. Infect Dis Clin North Am, 2019; 33(3):769–786; doi: 10.1016/j.idc.2019.04.005
12.
HayesR. Life Expectancy for People Living with HIV. 2021. Available from: https://www.aidsmap.com/about-hiv/life-expectancy-people-living-hiv [Last accessed: March13, 2023].
13.
MarcusJL, LeydenWA, AlexeeffSE, et al.Comparison of overall and comorbidity-free life expectancy between insured adults with and without HIV infection, 2000–2016. JAMA Netw Open, 2020; 3(6):e207954; doi: 10.1001/jamanetworkopen.2020.7954
14.
KuuselaP, SaraswatM, JoenvaaraS, et al.Changes in plasma protein levels as an early indication of a bloodstream infection. PLoS One, 2017; 12(2):e0172987; doi: 10.1371/journal.pone.0172987
15.
VadaqN, van de WijerL, van EekerenLE, et al.Targeted plasma proteomics reveals upregulation of distinct inflammatory pathways in people living with HIV. iScience, 2022; 25(10):105089; doi: 10.1016/j.isci.2022.105089
16.
HearpsAC, MaisaA, ChengWJ, et al.HIV infection induces age-related changes to monocytes and innate immune activation in young men that persist despite combination antiretroviral therapy. AIDS, 2012; 26(7):843–853; doi: 10.1097/QAD.0b013e328351f756
17.
ScientificTF. A Comparison of Protein Detection and Quantification Techniques. 2018. Available from: http://assets.thermofisher.com/TFS-Assets/BID/Application-Notes/comparison-protein-detection-quantification-techniques-application-note.pdf [Last accessed: March13, 2023].
18.
KrollKW, ShahSV, LucarOA, et al.Mucosal-homing natural killer cells are associated with aging in persons living with HIV. Cell Rep Med, 2022; 3(10):100773; doi: 10.1016/j.xcrm.2022.100773
19.
ValcourV, ShikumaC, ShiramizuB, et al.Higher frequency of dementia in older HIV-1 individuals: The Hawaii Aging with HIV-1 Cohort. Neurology, 2004; 63(5):822–827; doi: 10.1212/01.wnl.0000134665.58343.8d
ScientificTF. Cytokine & Chemokine Convenience 34-Plex Human ProcartaPlex™ Panel 1A. 2022. Available from: https://www.thermofisher.com/order/catalog/product/EPXR340-12167-901 [Last accessed: March13, 2023].
22.
RenAH, DiamandisEP, KulasingamV. Uncovering the depths of the human proteome: Antibody-based technologies for ultrasensitive multiplexed protein detection and quantification. Mol Cell Proteomics, 2021; 20:100155; doi: 10.1016/j.mcpro.2021.100155
23.
bio-techne. Luminex Assay Users Guide: A clear and easy guide to luminex multiplex immunoassays. n.d. Available from: https://www.bio-techne.com/reagents/luminex-assays/luminex-guide [Last accessed: March13, 2023].
NovateinBio. Sample Handling for ELISA Assay. 2022. Available from: https://novateinbio.com/content/85-sample-handling-for-elisa-assay [Last accessed: March13, 2023].
26.
MountjoyKG. ELISA versus LUMINEX assay for measuring mouse metabolic hormones and cytokines: Sharing the lessons I have learned. J Immunoassay Immunochem, 2021; 42(2):154–173; doi: 10.1080/15321819.2020.1838924
27.
ZhuY, AlapatiD, CostaJ, et al.A comparison of enzyme-linked immunosorbent assay versus multiplex methodology using an in vitro model of pulmonary hypertension and inflammation. J Biomed Sci Eng, 2014; 7:419–426; doi: 10.4236/jbise.2014.77044
28.
TeamRC. R: A Language and Environment for Statistical Computing. Vienna, Austria; 2021. Available from: https://www.R-project.org [Last accessed: March13, 2023].
29.
UlgenE, OzisikO, SezermanOU. pathfindR: An R package for comprehensive identification of enriched pathways in omics data through active subnetworks. Front Genet, 2019; 10:858; doi: 10.3389/fgene.2019.00858
30.
BatorskyR, SergeevRA, RouzineIM. The route of HIV escape from immune response targeting multiple sites is determined by the cost-benefit tradeoff of escape mutations. PLoS Comput Biol, 2014; 10(10):e1003878; doi: 10.1371/journal.pcbi.1003878
StanleyTL, GrinspoonSK. Body composition and metabolic changes in HIV-infected patients. J Infect Dis, 2012; 205Suppl 3:S383–S390; doi: 10.1093/infdis/jis205
33.
MusaF, ShaviyaN, MamboF, et al.Cytokine profiles in highly active antiretroviral treatment non-adherent, adherent and naive HIV-1 infected patients in Western Kenya. Afr Health Sci, 2021; 21(4):1584–1592; doi: 10.4314/ahs.v21i4.12
34.
BabuH, AmbikanAT, GabrielEE, et al.Systemic inflammation and the increased risk of inflamm-aging and age-associated diseases in people living with HIV on long term suppressive antiretroviral therapy. Front Immunol, 2019; 10:1965; doi: 10.3389/fimmu.2019.01965
35.
HilemanCO, FunderburgNT. Inflammation, immune activation, and antiretroviral therapy in HIV. Curr HIV/AIDS Rep, 2017; 14(3):93–100; doi: 10.1007/s11904-017-0356-x
36.
ThurmanM, JohnsonS, AcharyaA, et al.Biomarkers of activation and inflammation to track disparity in chronological and physiological age of people living with HIV on combination antiretroviral therapy. Front Immunol, 2020; 11:583934; doi: 10.3389/fimmu.2020.583934
37.
LiJZ, ArnoldKB, LoJ, et al.Differential levels of soluble inflammatory markers by human immunodeficiency virus controller status and demographics. Open Forum Infect Dis, 2015; 2(1):ofu117; doi: 10.1093/ofid/ofu117
38.
TenorioAR, ZhengY, BoschRJ, et al.Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment. J Infect Dis, 2014; 210(8):1248–1259; doi: 10.1093/infdis/jiu254
39.
RaphaelI, NalawadeS, EagarTN, et al.T cell subsets and their signature cytokines in autoimmune and inflammatory diseases. Cytokine, 2015; 74(1):5–17; doi: 10.1016/j.cyto.2014.09.011
40.
RomagnaniS. T-cell subsets (Th1 versus Th2). Ann Allergy Asthma Immunol, 2000; 85(1):9–18; quiz 18, 21; doi: 10.1016/S1081-1206(10)62426-X
41.
Valverde-VillegasJM, MatteMC, de MedeirosRM, et al.New insights about Treg and Th17 cells in HIV infection and disease progression. J Immunol Res, 2015; 2015:647916; doi: 10.1155/2015/647916
42.
Scientific TF. Inflammation and Cytokine Storm Assays. 2020. Available from: https://www.thermofisher.com/us/en/home/life-science/antibodies/immunoassays/procartaplex-assays-luminex/procartaplex-immunoassays/cytokine-panels.html [Last accessed: March13, 2023].
43.
FerrucciL, FabbriE. Inflammageing: Chronic inflammation in ageing, cardiovascular disease, and frailty. Nat Rev Cardiol, 2018; 15(9):505–522; doi: 10.1038/s41569-018-0064-2
OoYH, ShettyS, AdamsDH. The role of chemokines in the recruitment of lymphocytes to the liver. Dig Dis, 2010; 28(1):31–44; doi: 10.1159/000282062
46.
von AndrianUH, MackayCR. T-cell function and migration. Two sides of the same coin. N Engl J Med, 2000; 343(14):1020–1034; doi: 10.1056/NEJM200010053431407
47.
SureshP, WanchuA. Chemokines and chemokine receptors in HIV infection: Role in pathogenesis and therapeutics. J Postgrad Med, 2006; 52(3):210–217; PMID: 16855325
RameshG, MacLeanAG, PhilippMT. Cytokines and chemokines at the crossroads of neuroinflammation, neurodegeneration, and neuropathic pain. Mediators Inflamm, 2013; 2013:480739; doi: 10.1155/2013/480739
50.
NgcoboS, MolatlhegiRP, OsmanF, et al.Pre-infection plasma cytokines and chemokines as predictors of HIV disease progression. Sci Rep, 2022; 12(1):2437; doi: 10.1038/s41598-022-06532-w
51.
MitsuyasuRT. The potential role of interleukin-2 in HIV. AIDS, 2001; 15Suppl 2:S22–S27; doi: 10.1097/00002030-200102002-00005
52.
PettSL, KelleherAD, EmeryS. Role of interleukin-2 in patients with HIV infection. Drugs, 2010; 70(9):1115–1130; doi: 10.2165/10898620-000000000-00000
53.
EllwangerJH, Valverde-VillegasJM, KaminskiVL, et al.Increased IL-8 levels in HIV-infected individuals who initiated ART with CD4(+) T cell counts <350 cells/mm(3)—A potential hallmark of chronic inflammation. Microbes Infect, 2020; 22(9):474–480; doi: 10.1016/j.micinf.2020.05.019
54.
LaneBR, LoreK, BockPJ, et al.Interleukin-8 stimulates human immunodeficiency virus type 1 replication and is a potential new target for antiretroviral therapy. J Virol, 2001; 75(17):8195–8202; doi: 10.1128/jvi.75.17.8195-8202.2001
55.
TauG, RothmanP. Biologic functions of the IFN-gamma receptors. Allergy, 1999; 54(12):1233–1251; doi: 10.1034/j.1398-9995.1999.00099.x
56.
SparksR, KoelleDM, SternJE, et al.Elevated spontaneous interferon-gamma secretion in human immunodeficiency virus-infected persons. Open Forum Infect Dis, 2017; 4(2):ofx055; doi: 10.1093/ofid/ofx055
57.
WatanabeD, UehiraT, SuzukiS, et al.Clinical characteristics of HIV-1-infected patients with high levels of plasma interferon-gamma: A multicenter observational study. BMC Infect Dis, 2019; 19(1):11; doi: 10.1186/s12879-018-3643-2
58.
BandresE, MerinoJ, VazquezB, et al.The increase of IFN-gamma production through aging correlates with the expanded CD8(+high)CD28(-)CD57(+) subpopulation. Clin Immunol, 2000; 96(3):230–235; doi: 10.1006/clim.2000.4894
59.
EgeaL, HirataY, KagnoffMF. GM-CSF: A role in immune and inflammatory reactions in the intestine. Expert Rev Gastroenterol Hepatol, 2010; 4(6):723–731; doi: 10.1586/egh.10.73
60.
StaitiehBS, AuldSC, AhmedM, et al.Granulocyte macrophage-colony stimulating factor reverses HIV protein-induced mitochondrial derangements in alveolar macrophages. AIDS Res Hum Retroviruses, 2021; 37(3):224–232; doi: 10.1089/AID.2020.0176
61.
JunttilaIS. Tuning the cytokine responses: An update on interleukin (IL)-4 and IL-13 receptor complexes. Front Immunol, 2018; 9:888; doi: 10.3389/fimmu.2018.00888
OsujiFN, OnyenekweCC, AhanekuJE, et al.The effects of highly active antiretroviral therapy on the serum levels of pro-inflammatory and anti-inflammatory cytokines in HIV infected subjects. J Biomed Sci, 2018; 25(1):88; doi: 10.1186/s12929-018-0490-9
64.
GeeK, GuzzoC, Che MatNF, et al.The IL-12 family of cytokines in infection, inflammation and autoimmune disorders. Inflamm Allergy Drug Targets, 2009; 8(1):40–52; doi: 10.2174/187152809787582507
65.
LouisS, DutertreCA, VimeuxL, et al.IL-23 and IL-12p70 production by monocytes and dendritic cells in primary HIV-1 infection. J Leukoc Biol, 2010; 87(4):645–653; doi: 10.1189/jlb.1009684
KimCJ, McKinnonLR, KovacsC, et al.Mucosal Th17 cell function is altered during HIV infection and is an independent predictor of systemic immune activation. J Immunol, 2013; 191(5):2164–2173; doi: 10.4049/jimmunol.1300829
68.
FernandesJR, BerthoudTK, KumarA, et al.IL-23 signaling in Th17 cells is inhibited by HIV infection and is not restored by HAART: Implications for persistent immune activation. PLoS One, 2017; 12(11):e0186823; doi: 10.1371/journal.pone.0186823
69.
LeeS, FrenchMA, PriceP. IL-23 and IFN-gamma deficiency in immunodeficient HIV patients who achieved a long-term increase in CD4 T-cell counts on highly active antiretroviral therapy. AIDS, 2004; 18(9):1337–1340; doi: 10.1097/00002030-200406180-00014
70.
CavalliG, ColafrancescoS, EmmiG, et al.Interleukin 1alpha: A comprehensive review on the role of IL-1alpha in the pathogenesis and treatment of autoimmune and inflammatory diseases. Autoimmun Rev, 2021; 20(3):102763; doi: 10.1016/j.autrev.2021.102763
71.
de PaulaHHS, FerreiraACG, CaetanoDG, et al.Reduction of inflammation and T cell activation after 6 months of cART initiation during acute, but not in early chronic HIV-1 infection. Retrovirology, 2018; 15(1):76; doi: 10.1186/s12977-018-0458-6
72.
GinaldiL, De MartinisM, CiccarelliF, et al.Increased levels of interleukin 31 (IL-31) in osteoporosis. BMC Immunol, 2015; 16:60; doi: 10.1186/s12865-015-0125-9
73.
YanC, XuH, RongC, et al.IL-31 expression in HIV-infected patients with different routes of disease transmission. Medicine (Baltimore), 2022; 101(25):e29509; doi: 10.1097/MD.0000000000029509
74.
DillonSR, SprecherC, HammondA, et al.Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice. Nat Immunol, 2004; 5(7):752–760; doi: 10.1038/ni1084
75.
NobbeS, DziunyczP, MuhleisenB, et al.IL-31 expression by inflammatory cells is preferentially elevated in atopic dermatitis. Acta Derm Venereol, 2012; 92(1):24–28; doi: 10.2340/00015555-1191
76.
DoitshG, GreeneWC. Dissecting how CD4 T cells are lost during HIV infection. Cell Host Microbe, 2016; 19(3):280–291; doi: 10.1016/j.chom.2016.02.012
77.
Vidya VijayanKK, KarthigeyanKP, TripathiSP, et al.Pathophysiology of CD4+ T-cell depletion in HIV-1 and HIV-2 infections. Front Immunol, 2017; 8:580; doi: 10.3389/fimmu.2017.00580
78.
HokelloJ, SharmaAL, DimriM, et al.Insights into the HIV latency and the role of cytokines. Pathogens, 2019; 8(3):137; doi: 10.3390/pathogens8030137
79.
Gutierrez-RamosJC, LloydC, GonzaloJA. Eotaxin: From an eosinophilic chemokine to a major regulator of allergic reactions. Immunol Today, 1999; 20(11):500–504; doi: 10.1016/s0167-5699(99)01522-4
80.
BergerA. Th1 and Th2 responses: What are they?. BMJ, 2000; 321(7258):424; doi: 10.1136/bmj.321.7258.424
81.
TeixeiraAL, GamaCS, RochaNP, et al.Revisiting the role of eotaxin-1/CCL11 in psychiatric disorders. Front Psychiatry, 2018; 9:241; doi: 10.3389/fpsyt.2018.00241
82.
Gutierrez-RivasM, Jimenez-SousaMA, RallonN, et al.High plasma levels of sTNF-R1 and CCL11 are related to CD4+ T-cells fall in human immunodeficiency virus elite controllers with a sustained virologic control. Front Immunol, 2018; 9:1399; doi: 10.3389/fimmu.2018.01399
83.
DhawanP, RichmondA. Role of CXCL1 in tumorigenesis of melanoma. J Leukoc Biol, 2002; 72(1):9–18; PMID: 12101257
84.
ZengY, LinQ, YuL, et al.Chemokine CXCL1 as a potential marker of disease activity in systemic lupus erythematosus. BMC Immunol, 2021; 22(1):82; doi: 10.1186/s12865-021-00469-x
85.
ChenP, YiZ, ZhangW, et al.HIV infection-induced transcriptional program in renal tubular epithelial cells activates a CXCR2-driven CD4+ T-cell chemotactic response. AIDS, 2016; 30(12):1877–1888; doi: 10.1097/QAD.0000000000001153
86.
AngelovichTA, HearpsAC, MaisaA, et al.Viremic and virologically suppressed HIV infection increases age-related changes to monocyte activation equivalent to 12 and 4 years of aging, respectively. J Acquir Immune Defic Syndr, 2015; 69(1):11–17; doi: 10.1097/QAI.0000000000000559
87.
YinX, WangZ, WuT, et al.The combination of CXCL9, CXCL10 and CXCL11 levels during primary HIV infection predicts HIV disease progression. J Transl Med, 2019; 17(1):417; doi: 10.1186/s12967-019-02172-3
88.
AnsariAW, HeikenH, Meyer-OlsonD, et al.CCL2: A potential prognostic marker and target of anti-inflammatory strategy in HIV/AIDS pathogenesis. Eur J Immunol, 2011; 41(12):3412–3418; doi: 10.1002/eji.201141676
89.
ScullyE, LockhartA, HuangL, et al.Elevated levels of microbial translocation markers and CCL2 among older HIV-1-infected men. J Infect Dis, 2016; 213(5):771–775; doi: 10.1093/infdis/jiv501
90.
BhavsarI, MillerCS, Al-SabbaghM. Macrophage inflammatory protein-1 alpha (MIP-1 alpha)/CCL3: As a biomarker. Gen Methods Biomark Res Appl, 2015; 223–249; doi: 10.1007/978-94-007-7696-8_27
91.
BabaT, MukaidaN. Role of macrophage inflammatory protein (MIP)-1α/CCL3 in leukemogenesis. Mol Cell Oncol, 2014; 1(1):e29899; doi: 10.4161/mco.29899
92.
PetkovS, HerreraC, ElseL, et al.Mobilization of systemic CCL4 following HIV pre-exposure prophylaxis in young men in Africa. Front Immunol, 2022; 13:965214; doi: 10.3389/fimmu.2022.965214
93.
HutterG, NowakD, MossnerM, et al.Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med, 2009; 360(7):692–698; doi: 10.1056/NEJMoa0802905
94.
ZengZ, LanT, WeiY, et al.CCL5/CCR5 axis in human diseases and related treatments. Genes Dis, 2022; 9(1):12–27; doi: 10.1016/j.gendis.2021.08.004
95.
BorgesAH, SilverbergMJ, WentworthD, et al.Predicting risk of cancer during HIV infection: The role of inflammatory and coagulation biomarkers. AIDS, 2013; 27(9):1433–1441; doi: 10.1097/QAD.0b013e32835f6b0c
96.
BorgesAH, WeitzJI, CollinsG, et al.Markers of inflammation and activation of coagulation are associated with anaemia in antiretroviral-treated HIV disease. AIDS, 2014; 28(12):1791–1796; doi: 10.1097/QAD.0000000000000344
97.
GrivennikovSI, KarinM. Inflammatory cytokines in cancer: Tumour necrosis factor and interleukin 6 take the stage. Ann Rheum Dis, 2011; 70Suppl 1:i104–i108; doi: 10.1136/ard.2010.140145
98.
HarrisTB, FerrucciL, TracyRP, et al.Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med, 1999; 106(5):506–512; doi: 10.1016/s0002-9343(99)00066-2
99.
HashizumeM, HayakawaN, SuzukiM, et al.IL-6/sIL-6R trans-signalling, but not TNF-alpha induced angiogenesis in a HUVEC and synovial cell co-culture system. Rheumatol Int, 2009; 29(12):1449–1454; doi: 10.1007/s00296-009-0885-8
100.
Interleukin-6 Receptor Mendelian R and omisation Analysis C, Swerdlow DI, Holmes MV, et al. The interleukin-6 receptor as a target for prevention of coronary heart disease: A mendelian randomisation analysis. Lancet, 2012; 379(9822):1214–1224; doi: 10.1016/S0140-6736(12)60110-X
101.
KullerLH, TracyR, BellosoW, et al.Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med, 2008; 5(10):e203; doi: 10.1371/journal.pmed.0050203
102.
NakaharaH, SongJ, SugimotoM, et al.Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis. Arthritis Rheum, 2003; 48(6):1521–1529; doi: 10.1002/art.11143
103.
PoliV, BalenaR, FattoriE, et al.Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion. EMBO J, 1994; 13(5):1189–1196; doi: 10.1002/j.1460-2075.1994.tb06368.x
104.
RajDS. Role of interleukin-6 in the anemia of chronic disease. Semin Arthritis Rheum, 2009; 38(5):382–388; doi: 10.1016/j.semarthrit.2008.01.006
105.
BorgesAH, O'ConnorJL, PhillipsAN, et al.Factors associated with plasma IL-6 levels during HIV infection. J Infect Dis, 2015; 212(4):585–595; doi: 10.1093/infdis/jiv123
106.
JangDI, LeeAH, ShinHY, et al.The role of tumor necrosis factor alpha (TNF-alpha) in autoimmune disease and current TNF-alpha inhibitors in therapeutics. Int J Mol Sci, 2021; 22(5):2719; doi: 10.3390/ijms22052719
107.
De Pablo-BernalRS, Ruiz-MateosE, RosadoI, et al.TNF-alpha levels in HIV-infected patients after long-term suppressive cART persist as high as in elderly, HIV-uninfected subjects. J Antimicrob Chemother, 2014; 69(11):3041–3046; doi: 10.1093/jac/dku263
108.
SwaminathanS, QiuJ, RupertAW, et al.Interleukin-15 (IL-15) strongly correlates with increasing HIV-1 viremia and markers of inflammation. PLoS One, 2016; 11(11):e0167091; doi: 10.1371/journal.pone.0167091
109.
VerbistKC, KlonowskiKD. Functions of IL-15 in anti-viral immunity: Multiplicity and variety. Cytokine, 2012; 59(3):467–478; doi: 10.1016/j.cyto.2012.05.020
110.
HazeldineJ, LordJM. The impact of ageing on natural killer cell function and potential consequences for health in older adults. Ageing Res Rev, 2013; 12(4):1069–1078; doi: 10.1016/j.arr.2013.04.003
111.
KleinSL, FlanaganKL. Sex differences in immune responses. Nat Rev Immunol, 2016; 16(10):626–638; doi: 10.1038/nri.2016.90
112.
VanpouilleC, WellsA, WilkinT, et al.Sex differences in cytokine profiles during suppressive antiretroviral therapy. AIDS, 2022; 36(9):1215–1222; doi: 10.1097/QAD.0000000000003265
113.
AraujoLS, TorquatoBGS, da SilvaCA, et al.Renal expression of cytokines and chemokines in diabetic nephropathy. BMC Nephrol, 2020; 21(1):308; doi: 10.1186/s12882-020-01960-0
114.
ElisiaI, LamV, ChoB, et al.The effect of smoking on chronic inflammation, immune function and blood cell composition. Sci Rep, 2020; 10(1):19480; doi: 10.1038/s41598-020-76556-7
115.
FiorenzaCG, ChouSH, MantzorosCS. Lipodystrophy: Pathophysiology and advances in treatment. Nat Rev Endocrinol, 2011; 7(3):137–150; doi: 10.1038/nrendo.2010.199
116.
HarakehS, KalamegamG, PushparajPN, et al.Chemokines and their association with body mass index among healthy Saudis. Saudi J Biol Sci, 2020; 27(1):6–11; doi: 10.1016/j.sjbs.2019.03.006
117.
LarssonA, CarlssonL, LindAL, et al.The body mass index (BMI) is significantly correlated with levels of cytokines and chemokines in cerebrospinal fluid. Cytokine, 2015; 76(2):514–518; doi: 10.1016/j.cyto.2015.07.010
118.
MakkiK, FroguelP, WolowczukI. Adipose tissue in obesity-related inflammation and insulin resistance: Cells, cytokines, and chemokines. ISRN Inflamm, 2013; 2013:139239; doi: 10.1155/2013/139239
119.
PanX, KamingaAC, WenSW, et al.Chemokines in prediabetes and type 2 diabetes: A meta-analysis. Front Immunol, 2021; 12:622438; doi: 10.3389/fimmu.2021.622438
120.
RanderiaSN, ThomsonGJA, NellTA, et al.Inflammatory cytokines in type 2 diabetes mellitus as facilitators of hypercoagulation and abnormal clot formation. Cardiovasc Diabetol, 2019; 18(1):72; doi: 10.1186/s12933-019-0870-9
121.
SilvaRE, SantosEC, JustinoPBI, et al.Cytokines and chemokines systemic levels are related to dialysis adequacy and creatinine clearance in patients with end-stage renal disease undergoing hemodialysis. Int Immunopharmacol, 2021; 100:108154; doi: 10.1016/j.intimp.2021.108154
122.
WangH, ChenH, FuY, et al.Effects of smoking on inflammatory-related cytokine levels in human serum. Molecules, 2022; 27(12):3715; doi: 10.3390/molecules27123715
123.
SheblFM, YuK, LandgrenO, et al.Increased levels of circulating cytokines with HIV-related immunosuppression. AIDS Res Hum Retroviruses, 2012; 28(8):809–815; doi: 10.1089/AID.2011.0144
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
